Dark

Check out our Level2View

BIOVF
SWEDISH ORPHAN BIOVIT ORD
stock OTC

EOD

Jul 28, 2026

48.21USD-1.679%(-0.82)1,500

Pre-market

0.00USD-100.000%(-49.03)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Dec 15, 2021

10:14AM EST Apellis - Sobi's Pegcetacoplan Wins European Approval For Rare Blood Disorder Benzinga

Dec 3, 2021

06:50AM EST AstraZeneca Blocks SOBI's $8B Buyout, Advent Withdraws The Bid - Report Benzinga

Feb 24, 2021

10:07AM EST Benzinga's Top Ratings Upgrades, Downgrades For February 24, 2021 Benzinga

08:23AM EST Barclays Downgrades Swedish Orphan Biovitrum to Equal-Weight Benzinga

Dec 10, 2020

02:25AM EST Sobi Aims To Reach Revenues Of SEK 25 Bln In 2025 RTTNews

02:15AM EST Realising opportunities for future growth and financial update: Sobi Capital PR Newswire

Nov 4, 2020

02:55AM EST Sobi launch Doptelet(r) (avatrombopag) in Europe PR Newswire

Oct 22, 2020

03:05AM EDT Swedish Orphan Biovitrum Q3 EPS SEK 0.94 Vs SEK 1.84 Last Year RTTNews

02:41AM EDT Sobi publishes report for the third quarter 2020 PR Newswire

Oct 9, 2020

07:39AM EDT Sobi Announces Phase 3 Data Of Avatrombopag For Treatment Of Chemotherapy-Induced Thrombocytopenia RTTNews

07:37AM EDT Sobi announces topline phase 3 data of avatrombopag for the treatment of PR Newswire

Oct 7, 2020

02:52AM EDT Invitation - Presentation of Sobi's Q3 2020 results PR Newswire

Sep 30, 2020

05:44PM EDT COMPARE study supporting the potential for important clinical improvement in patients with Chronic Refractory Gout PR Newswire

Jul 28, 2020

06:23AM EDT Sobi and Selecta Announce Closing of Previously Announced Strategic Licensing Agreement for Sel-212, a Phase 3-ready Novel Treatment for Chronic Refractory Gout Benzinga

Share